triadaxs.blogg.se - Advair discus dosage

A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Patients who use corticosteroids are at risk for potential worsening of existing tuberculosis fungal, bacterial, viral, or parasitic infections or ocular herpes simplex.

Monitor patients for signs and symptoms of pneumonia. There is an increased risk of pneumonia with WIXELA INHUB in patients with COPD.

Advise patients to rinse the mouth with water without swallowing following inhalation to help reduce the risk of oropharyngeal candidiasis.

Candida albicans has occurred in patients treated with fluticasone propionate and salmeterol inhalation powder.

Patients using WIXELA INHUB should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

WIXELA INHUB should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result.

An inhaled, short-acting beta 2-agonist, not WIXELA INHUB, should be used to relieve acute symptoms such as shortness of breath.

WIXELA INHUB should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm.

WIXELA INHUB should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD.

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. These findings are considered a class effect of LABA monotherapy.

LABA monotherapy for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients, available data also suggest an increased risk of asthma-related hospitalization.